SELLAS Life Sciences Group, Inc. (SLS) News
Follow SELLAS Life Sciences Group, Inc. (SLS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 35 public stories across 24 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
State Street reports 5.1% stake in Sellas Life Sciences
State Street reported a 5.1% stake in Sellas Life Sciences. Victory Capital also disclosed a nearly 1,000% increase in its holdings; the supplied text does not specify the resulting stake.
EQUITY | Nov 11, 2026, 01:36 AM UTC
M
Sellas Life Sciences Shares Rise 0.4% Overnight After Citi Stake Cut
Sellas Life Sciences shares rose 0.4% overnight after Citigroup disclosed a nearly 64% reduction in its stake. Shares gained 3% Wednesday to $9.14 and remained down nearly 6% for the week.
EQUITY | Nov 05, 2026, 02:33 AM UTC
M
Sellas Life Sciences Shares Fall 12% to $8.55, Hit One-Month Low
Sellas Life Sciences shares fell 12% to $8.55 on Monday, their lowest level in more than a month. Disclosures showed several investment firms increased their third-quarter holdings by as much as 422%, ahead of cancer dat
EQUITY | Nov 03, 2026, 01:22 AM UTC
M
Sellas Life Sciences shares fall 15% to $10.38
Sellas Life Sciences shares ended Wednesday 15% lower at $10.38 as the company moved closer to a key cancer-drug readout.
EQUITY | Oct 29, 2026, 03:02 AM UTC
L
Sellas GPS Trial Records 80th Event, Triggering Final Analysis
Sellas Life Sciences said its Phase 3 REGAL trial of galinpepimut-S recorded its 80th death, triggering the final analysis.
EQUITY | Oct 28, 2026, 04:09 PM UTC
L
Sellas Life Sciences Reaches Milestone in Phase 3 REGAL Trial
Sellas Life Sciences said its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia has reached an event milestone.
EQUITY | Oct 28, 2026, 12:46 PM UTC
M
Sellas Life Sciences Shares Rise 5% to $10.49
Sellas Life Sciences shares rose 5% on Monday to $10.49, ending a three-session losing streak. Retail investors also discussed potential buyout scenarios after CEO Angelos Stergiou marked the company’s 15th anniversary.
EQUITY | Oct 20, 2026, 04:07 AM UTC
M
U.S. Stock Futures Gain 0.2% Ahead of Earnings Season
As of 4:00 a.m. ET, Nasdaq, S&P 500, Dow and Russell 2000 futures were each up 0.2% as investors prepared for the start of third-quarter earnings season. Major U.S. banks are reporting, with ASML and TSMC also due this w
EQUITY | Oct 12, 2026, 08:43 AM UTC
M
Sellas Life Sciences (SLS) falls 0.3% to $11.31
SLS shares slipped 0.3% to $11.31, ending a two-week winning streak narrative with a third straight session of losses as leukemia research circulated ahead of Regal’s final-analysis milestone.
EQUITY | Oct 08, 2026, 03:55 AM UTC
L
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Biotech stocks trailed the S&P 500 and Nasdaq-100 in September, yet Iovance Biotherapeutics (IOVA) and ImmunityBio (IBRX) bucked the sector’s decline, while Sellas Life Sciences (SLS) awaited key leukemia data and Vanda
NEWS | Sep 30, 2026, 03:48 AM UTC
L
Weekly Recap: SLS009 Phase 2 enrollment and REGAL 78 of 80 events
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is advancing SLS009 in a Phase 2 AML trial with 28 of 80 patients enrolled and topline data due Q4 2026, while its blinded, event—driven REGAL study reports 78 of 80 deaths a
EQUITY | Sep 28, 2026, 11:06 AM UTC
L
SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered
SELLAS Life Sciences (SLS) shares fell about 3% on Friday after lab tests of its experimental drug SLS009 in dish-grown pancreatic tumors showed strong cell-killing but answered neither question the stock is priced on.Th
EQUITY | Sep 25, 2026, 08:37 PM UTC
L
SELLAS Life Sciences Group, Inc. (SLS) Reports Preclinical SLS009 Activity in PDAC Models
SELLAS reported preclinical data showing SLS009 (CDK9 inhibitor) activity in MYC—amplified pancreatic cancer organoid models, including a daraxonrasib—resistant model, and synergy with BET inhibitor ZEN3694.Material Deta
NEWS | Sep 25, 2026, 05:01 PM UTC
L
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. NASDAQ:SLS (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a b
NEWS | Sep 25, 2026, 05:01 PM UTC
L
SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial
Shares of Sellas Life Sciences (SLS) slipped 1% overnight heading into Thursday ahead of a pancreatic cancer conference where the company will present three early-stage studies of its second cancer drug, SLS009. The trea
EQUITY | Sep 24, 2026, 05:00 AM UTC
L
Communities Finalise Life Plans Alongside Renewed Shuar Agreements as Warintza Continues to Advance De-Risking Activities
HIGHLIGHTS OF THE PRESS RELEASE:QUITO, Ecuador, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (“Solaris” or the “Company”) (TSX: SLS; NYSE: SLSR) is pleased to provide an update on the continued advancement o
EQUITY | Sep 10, 2026, 11:01 AM UTC
L
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
Sellas Life Sciences (SLS) and ImmunityBio (IBRX) drew attention on Wednesday after Canadian insurance giant Manulife’s principal operating insurer disclosed that it increased its institutional stakes in both cancer-drug
EQUITY | Sep 10, 2026, 03:04 AM UTC
L
Sellas to present new preclinical SLS009 data for pancreatic cancer
Sellas Life Sciences said three abstracts for SLS009 (Tambiciclib) have been accepted for poster presentation at a major oncology conference.
EQUITY | Sep 02, 2026, 02:56 PM UTC
L
SELLAS to present preclinical SLS009 data at 2026 AACR pancreatic conference
SELLAS Life Sciences will present preclinical data on SLS009 (tambiciclib) at the 2026 AACR Conference on Pancreatic Cancer.
EQUITY | Sep 02, 2026, 12:37 PM UTC
L
SELLAS Life Sciences to present preclinical data on SLS009 at AACR 2026
SELLAS Life Sciences plans to present preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer.
EQUITY | Sep 02, 2026, 12:31 PM UTC
L
SLS - is in a quiet period but the CEO keeps posting on LinkedIn to keep his cult investors on the hook. -- ADAM F STAT News
SLS - is in a quiet period but the CEO keeps posting on LinkedIn to keep his cult investors on the hook. -- ADAM F STAT News
EQUITY | Aug 31, 2026, 05:13 PM UTC
L
Sellas CEO Stergiou backs ‘rigorous, unblinded’ REGAL AML data
Sellas CEO Stergiou said rigorous, unblinded data from its pivotal AML trial will speak for itself as the REGAL catalyst nears.
EQUITY | Aug 31, 2026, 02:21 PM UTC
L
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger
EQUITY | Aug 31, 2026, 02:30 AM UTC
L
Solstice Minerals extends Nanadie copper-gold system beyond 700m
Solstice Minerals says it has extended the Nanadie copper-gold system beyond 700m depth.
COMMODITIES | Aug 28, 2026, 12:16 AM UTC
L
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
EQUITY | Aug 27, 2026, 07:10 AM UTC
L
RVMD drug approval chatter; SLS leukemia pipeline focus
TradingView News says market attention is on RVMD’s drug approval, while near-term focus remains on SLS’s leukemia pipeline.
EQUITY | Aug 26, 2026, 10:22 PM UTC
L
SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
EQUITY | Aug 26, 2026, 08:12 AM UTC
L
SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate
SELLAS Life Sciences Gr (NASDAQ: SLS ) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of $(0.07) per shar
EARNINGS | Aug 11, 2026, 08:19 PM UTC
L
SLS - SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SLS - SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 11, 2026, 08:06 PM UTC
L
SLS Sellas Life Sciences group - arbitrator dismisses company's claims in arbitration against 3d Medicines on July 24, 2026 - SEC filing - C
SLS Sellas Life Sciences group - arbitrator dismisses company's claims in arbitration against 3d Medicines on July 24, 2026 - SEC filing - Company to pay about $1M of 3d Medicines' legal fees - SEC filing
REGULATION | Jul 27, 2026, 08:37 PM UTC
H
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Nasdaq Composite falling around 400 points on Friday. Shares of ManpowerGroup Inc (NYSE: MAN ) rose sharply after the company reported upbeat second-quarter results and issued third-quart
EARNINGS | Jul 17, 2026, 02:09 PM UTC
L
SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?
SELLAS Life Sciences Group Inc (NASDAQ: SLS ) shares are trading lower Tuesday as traders digest the recent breakout run and early profit-taking shows up even with momentum still elevated from the company’s latest corpor
EARNINGS | Jun 30, 2026, 01:39 PM UTC
M
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises In c (NASDAQ: APOG ) rose sharply after the company reported better-than-expected first-quarter financ
EARNINGS | Jun 26, 2026, 01:39 PM UTC
M
12 Health Care Stocks Move
Multiple health care stocks are moving in Thursday's intraday session, with gainers including Atlantic International and SELLAS Life Sciences, and losers including Nano X Imaging and Passage Bio
EQUITY | Jun 25, 2026, 05:05 PM UTC